[go: up one dir, main page]

WO2004092145A8 - Acides carboxyliques alpha-substitues comme modulateurs du recepteur active par les proliferateurs de peroxysome (ppar) - Google Patents

Acides carboxyliques alpha-substitues comme modulateurs du recepteur active par les proliferateurs de peroxysome (ppar)

Info

Publication number
WO2004092145A8
WO2004092145A8 PCT/IB2004/001159 IB2004001159W WO2004092145A8 WO 2004092145 A8 WO2004092145 A8 WO 2004092145A8 IB 2004001159 W IB2004001159 W IB 2004001159W WO 2004092145 A8 WO2004092145 A8 WO 2004092145A8
Authority
WO
WIPO (PCT)
Prior art keywords
formula
substituted carboxylic
carboxylic acid
alpha substituted
ppar modulators
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2004/001159
Other languages
English (en)
Other versions
WO2004092145A1 (fr
Inventor
Simon Bailey
Paul Stuart Humphries
Donald James Skalitzky
Wei-Guo Su
Luke Raymond Zehnder
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Corp Belgium
Pfizer Corp SRL
Original Assignee
Pfizer Corp Belgium
Pfizer Corp SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AP2005003418A priority Critical patent/AP2005003418A0/xx
Priority to EP04725121A priority patent/EP1615899A1/fr
Priority to CA002521915A priority patent/CA2521915A1/fr
Priority to AU2004230316A priority patent/AU2004230316A1/en
Priority to EA200501462A priority patent/EA200501462A1/ru
Priority to MXPA05010967A priority patent/MXPA05010967A/es
Priority to BRPI0409429-8A priority patent/BRPI0409429A/pt
Application filed by Pfizer Corp Belgium, Pfizer Corp SRL filed Critical Pfizer Corp Belgium
Priority to JP2006506478A priority patent/JP2006523671A/ja
Publication of WO2004092145A1 publication Critical patent/WO2004092145A1/fr
Publication of WO2004092145A8 publication Critical patent/WO2004092145A8/fr
Priority to IS8033A priority patent/IS8033A/is
Priority to TNP2005000262A priority patent/TNSN05262A1/fr
Anticipated expiration legal-status Critical
Priority to NO20055370A priority patent/NO20055370L/no
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C07D213/66—One oxygen atom attached in position 3 or 5 having in position 3 an oxygen atom and in each of the positions 4 and 5 a carbon atom bound to an oxygen, sulphur, or nitrogen atom, e.g. pyridoxal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/14—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by halogen atoms or by nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/16—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C317/22—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C62/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C62/30—Unsaturated compounds
    • C07C62/34—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Furan Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des acides carboxyliques alpha-substitués de formule (I), dans laquelle R1 et R2 ont la définition donnée dans la description et R3 est représenté par les formules (A), (B), (C) et (D), dans lesquelles Y, Ar1, Ar2, Ar3, R4, R5, R6, R7, R8, R9, R9a, R10, R11, R12, R17, le cycle A, et p ont la définition donnée dans la description ; et des compositions pharmaceutiques qui contiennent des quantités efficaces de ces composés ou de leurs sels utiles pour traiter des troubles associés au PPAR, plus spécifiquement au PPAR α/η, tels que le diabète, la dyslipidémie, l'obésité et les maladies inflammatoires.
PCT/IB2004/001159 2003-04-15 2004-04-01 Acides carboxyliques alpha-substitues comme modulateurs du recepteur active par les proliferateurs de peroxysome (ppar) Ceased WO2004092145A1 (fr)

Priority Applications (11)

Application Number Priority Date Filing Date Title
MXPA05010967A MXPA05010967A (es) 2003-04-15 2004-04-01 Acidos carboxilicos alfa sustituidos como moduladores ppar.
EP04725121A EP1615899A1 (fr) 2003-04-15 2004-04-01 Acides carboxyliques alpha-substitues comme modulateurs du recepteur active par les proliferateurs de peroxysome (ppar)
CA002521915A CA2521915A1 (fr) 2003-04-15 2004-04-01 Acides carboxyliques alpha-substitues comme modulateurs du recepteur active par les proliferateurs de peroxysome (ppar)
AU2004230316A AU2004230316A1 (en) 2003-04-15 2004-04-01 Alpha substituted carboxylic acid as PPAR modulators
EA200501462A EA200501462A1 (ru) 2003-04-15 2004-04-01 Альфа-замещенные карбоновые кислоты в качестве модуляторов ppar
BRPI0409429-8A BRPI0409429A (pt) 2003-04-15 2004-04-01 ácido carboxìlico substituìdo na posição alfa como moduladores ppar
JP2006506478A JP2006523671A (ja) 2003-04-15 2004-04-01 ＰＰＡＲ調節剤としてのα置換カルボン酸
AP2005003418A AP2005003418A0 (en) 2003-04-15 2004-04-01 Alpha substituted carboxylic acids as ppar modulators.
IS8033A IS8033A (is) 2003-04-15 2005-09-15 Alfa setnar karboxýlískar sýrur sem PPAR miðlar
TNP2005000262A TNSN05262A1 (fr) 2003-04-15 2005-10-14 Acides carboxyliques alpha-substitues servant de modulateurs de ppar
NO20055370A NO20055370L (no) 2003-04-15 2005-11-14 Alfa-substituert karboksylsyre som PPAR modulatorer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46321303P 2003-04-15 2003-04-15
US60/463,213 2003-04-15

Publications (2)

Publication Number Publication Date
WO2004092145A1 WO2004092145A1 (fr) 2004-10-28
WO2004092145A8 true WO2004092145A8 (fr) 2005-05-12

Family

ID=33300053

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2004/001159 Ceased WO2004092145A1 (fr) 2003-04-15 2004-04-01 Acides carboxyliques alpha-substitues comme modulateurs du recepteur active par les proliferateurs de peroxysome (ppar)

Country Status (25)

Country Link
EP (1) EP1615899A1 (fr)
JP (1) JP2006523671A (fr)
KR (1) KR20060009846A (fr)
CN (1) CN1805943A (fr)
AP (1) AP2005003418A0 (fr)
AR (1) AR044514A1 (fr)
AU (1) AU2004230316A1 (fr)
BR (1) BRPI0409429A (fr)
CA (1) CA2521915A1 (fr)
CL (1) CL2004000800A1 (fr)
EA (1) EA200501462A1 (fr)
EC (1) ECSP056105A (fr)
IS (1) IS8033A (fr)
MA (1) MA27764A1 (fr)
MX (1) MXPA05010967A (fr)
NL (1) NL1025946C2 (fr)
NO (1) NO20055370L (fr)
OA (1) OA13157A (fr)
PA (1) PA8600201A1 (fr)
PE (1) PE20050415A1 (fr)
TN (1) TNSN05262A1 (fr)
TW (1) TW200510353A (fr)
UY (1) UY28266A1 (fr)
WO (1) WO2004092145A1 (fr)
ZA (1) ZA200508362B (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005247473A1 (en) * 2004-05-25 2005-12-08 Metabolex, Inc. Substituted triazoles as modulators of PPAR and methods of their preparation
NZ563866A (en) 2005-05-09 2011-03-31 Achillion Pharmaceuticals Inc Thiazole compounds and methods of use
EA017198B1 (ru) 2006-10-30 2012-10-30 Хрома Терапьютикс Лтд. Гидроксаматы в качестве ингибиторов гистон-деацетилазы
ES2445049T3 (es) 2007-03-08 2014-02-27 Albireo Ab Derivados del ácido 3-fenilpropiónico y su uso en el tratamiento de la enfermedad inflamatoria intestinal
CN101801964A (zh) 2007-05-22 2010-08-11 艾其林医药公司 杂芳基取代的噻唑及其作为抗病毒剂的用途
US8106209B2 (en) 2008-06-06 2012-01-31 Achillion Pharmaceuticals, Inc. Substituted aminothiazole prodrugs of compounds with anti-HCV activity
CA2729909A1 (fr) 2008-07-14 2010-01-21 Gilead Sciences, Inc. Composes inhibiteurs de pyrimidine imidazolyle
AU2009271019A1 (en) 2008-07-14 2010-01-21 Gilead Sciences, Inc. Fused heterocyclyc inhibitors of histone deacetylase and/or cyclin-dependent kinases
EP2303841A1 (fr) 2008-07-14 2011-04-06 Gilead Sciences, Inc. Composés inhibiteurs de l oxindolyle
BRPI0916713A2 (pt) 2008-07-28 2015-11-10 Gilead Science Inc compostos inibidores de histona desacetilase de cicloalquilideno e heterocicloalquilideno
CN102803204A (zh) 2009-06-08 2012-11-28 吉利德科学股份有限公司 环烷基氨基甲酸酯苯酰胺苯胺hdac抑制剂化合物
EP2440519A1 (fr) 2009-06-08 2012-04-18 Gilead Sciences, Inc. Composés inhibiteurs d'hdac à base d'alkanoylamino benzamide aniline
DE102010055499A1 (de) * 2010-12-22 2011-06-16 W.C. Heraeus Gmbh Prozess zur Herstellung von Bendamustinalkylester, Bendarmustin sowie Derivaten davon
KR20140105445A (ko) 2011-10-31 2014-09-01 제논 파마슈티칼스 인크. 비아릴 에테르 술폰아미드 및 치료제로서의 그의 용도
BR112014010271A2 (pt) 2011-10-31 2017-04-18 Xenon Pharmaceuticals Inc compostos de benzenossulfonamida e seu uso como agentes terapêuticos
FR2982858B1 (fr) * 2011-11-18 2013-11-29 Rhodia Operations Procede de fabrication de composes comprenant des fonctions nitriles
FR2984322B1 (fr) * 2011-12-16 2013-12-20 Rhodia Operations Procede de fabrication de composes comprenant des fonctions nitriles
PE20150400A1 (es) 2012-05-22 2015-03-27 Genentech Inc Benzamidas n-sustituidas y su uso en el tratamiento del dolor
CA2878478A1 (fr) 2012-07-06 2014-01-09 Genentech, Inc. Benzamides n-substitues et leurs procedes d'utilisation
JP6096370B2 (ja) 2013-03-14 2017-03-15 ジェネンテック， インコーポレイテッド 置換トリアゾロピリジンとその使用方法
JP6227112B2 (ja) 2013-03-15 2017-11-08 ジェネンテック， インコーポレイテッド 置換ベンゾオキサゾールとその使用方法
WO2015078374A1 (fr) 2013-11-27 2015-06-04 Genentech, Inc. Benzamides substitués et leurs méthodes d'utilisation
CN106715418A (zh) 2014-07-07 2017-05-24 基因泰克公司 治疗化合物及其使用方法
AU2016268120A1 (en) 2015-05-22 2017-11-30 Genentech, Inc. Substituted benzamides and methods of use thereof
JP2018526371A (ja) 2015-08-27 2018-09-13 ジェネンテック， インコーポレイテッド 治療化合物及びその使用方法
WO2017058821A1 (fr) 2015-09-28 2017-04-06 Genentech, Inc. Composés thérapeutiques et leurs procédés d'utilisation
EP3380466A1 (fr) 2015-11-25 2018-10-03 Genentech, Inc. Benzamides substitués utiles en tant que bloqueurs de canaux sodiques
JP2019513714A (ja) 2016-03-30 2019-05-30 ジェネンテック， インコーポレイテッド 置換ベンズアミド及びその使用方法
CA3039853A1 (fr) 2016-10-17 2018-04-26 Genentech, Inc. Composes therapeutiques et leurs procedes d'utilisation
WO2018175707A1 (fr) 2017-03-24 2018-09-27 Genentech, Inc. Dérivés de 4-pipéridine-n-(pyrimidin-4-yl) chromane-7-sulfonamide en tant qu'inhibiteurs de canaux sodiques
WO2019165290A1 (fr) 2018-02-26 2019-08-29 Genentech, Inc. Composés de pyridine-sulfonamide et leur utilisation contre la douleur et les états associés
WO2019191702A1 (fr) 2018-03-30 2019-10-03 F. Hoffmann-La Roche Ag Hydro-pyrido-azines substituées utilisées comme inhibiteurs du canal sodique
TW202003490A (zh) 2018-05-22 2020-01-16 瑞士商赫孚孟拉羅股份公司 治療性化合物及其使用方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1088824E (pt) * 1999-09-30 2004-04-30 Pfizer Prod Inc Pirrolil-amidas biciclicas como inibidores de glicogenio-fosforilase
CA2438492A1 (fr) * 2001-02-15 2002-08-22 Pfizer Products Inc. Composes de recepteurs actives de la proliferation des peroxysomes (ppar)

Also Published As

Publication number Publication date
WO2004092145A1 (fr) 2004-10-28
NO20055370L (no) 2006-01-12
CN1805943A (zh) 2006-07-19
CL2004000800A1 (es) 2005-03-04
JP2006523671A (ja) 2006-10-19
NO20055370D0 (no) 2005-11-14
AU2004230316A1 (en) 2004-10-28
TNSN05262A1 (fr) 2007-07-10
AP2005003418A0 (en) 2005-12-31
CA2521915A1 (fr) 2004-10-28
MXPA05010967A (es) 2005-11-28
PE20050415A1 (es) 2005-06-13
ECSP056105A (es) 2006-03-01
UY28266A1 (es) 2004-11-30
EA200501462A1 (ru) 2006-04-28
PA8600201A1 (es) 2005-02-04
EP1615899A1 (fr) 2006-01-18
AR044514A1 (es) 2005-09-14
IS8033A (is) 2005-09-15
TW200510353A (en) 2005-03-16
BRPI0409429A (pt) 2006-04-18
NL1025946C2 (nl) 2005-02-01
ZA200508362B (en) 2006-11-29
NL1025946A1 (nl) 2004-10-18
MA27764A1 (fr) 2006-02-01
KR20060009846A (ko) 2006-02-01
OA13157A (en) 2006-12-13

Similar Documents

Publication Publication Date Title
WO2004092145A8 (fr) Acides carboxyliques alpha-substitues comme modulateurs du recepteur active par les proliferateurs de peroxysome (ppar)
HUT77372A (hu) Új benzil-pirimidinek, ezeket tartalmazó gyógyszerkészítmények és eljárás előállításukra
TW345575B (en) Pharmaceutical composition comprising an inhibitor for ras farnesylation and the preparation of the inhibitor compound
MY147780A (en) Carboxamide compounds and their use as calpain inhibitors
AR034556A1 (es) Un derivado de fenilalanina, una composicion farmaceutica que comprende al derivado de fenilalanina, el uso del derivado y proceso para preparar dicho derivado
CA2472954A1 (fr) Aza-arylpiperazines
CA2430601A1 (fr) Derives de piperazine
CA2417106A1 (fr) Derives de la piperazine
WO2002015662A3 (fr) Fractions heteroaryle substituees par quinuclidine destinees au traitement de maladies
CA2445145A1 (fr) Derives d'oxazole substitues par de l'acide carboxylique utiles en tant qu'activateurs ppar-alpha et gamma dans le traitement du diabete
MXPA04000891A (es) Nuevos derivados de acido vinilcarboxilico y su uso como antidiabeticos.
AR037460A1 (es) Compuesto de hidroxietileno, composicion farmaceutica que lo comprende, uso del mismo para la fabricacion de un medicamento y procedimiento para su preparacion
GEP20104959B (en) Bicyclic [3.1.0] derivatives as glycine transporter inhibitors
MY147588A (en) (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetic acid derivatives
TR200201168T2 (tr) CGRP-Antagonistleri-yeni siklopropanlar içeren ilaçlar ve üretim yöntemleri.
DK1513519T3 (da) Anvendelse af substituerede cyanopyrrolidiner til behandling af hyperlipidæmi
WO2002072584A3 (fr) Derives de la piperazine
WO2004041802A8 (fr) Derives de 4(phenyl-piperazinyl-methyl) benzamide et utilisation de ceux-ci pour le traitement de la douleur et des troubles gastro-intestinaux
ATE455761T1 (de) Neue atorvastatinsalze und pharmazeutische zusammensetzungen, die diese enthalten
DE60134735D1 (de) Neue neurokinin-antagonisten zum gebrauch als arzneimittel
ZA200704913B (en) 3-[2-(3-acylamino-2-oxo-2H-pyridin-1-YL)-acetylamino]-4-oxo-pentanoic acid derivatives and their use as caspase inhibitors
WO2005000840A8 (fr) Dicetopiperazines substituees et leur utilisation comme antagonistes de l'ocytocine
TR200402720T4 (tr) Metalloproteaz inhibitörleri olarak 2-(4-piridinil)-benzofüran'lar
ATE469882T1 (de) Neue verbindungen, die sich f r die behandlung von durch ppar vermittelten krankheiten eignen
DE60110233D1 (de) Neue n-(2-phenyl-3-aminopropyl)naphtamide

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WR Later publication of a revised version of an international search report
WWE Wipo information: entry into national phase

Ref document number: 2004230316

Country of ref document: AU

Ref document number: 4134/DELNP/2005

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 171046

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 20050342

Country of ref document: UZ

WWE Wipo information: entry into national phase

Ref document number: 542803

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2004230316

Country of ref document: AU

Date of ref document: 20040401

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004230316

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2521915

Country of ref document: CA

Ref document number: 05102555

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 2004725121

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: PA/a/2005/010967

Country of ref document: MX

Ref document number: P-2005/0768

Country of ref document: YU

Ref document number: CR2005-008039

Country of ref document: CR

WWE Wipo information: entry into national phase

Ref document number: 9016

Country of ref document: GE

WWE Wipo information: entry into national phase

Ref document number: 1020057019591

Country of ref document: KR

Ref document number: 200508362

Country of ref document: ZA

Ref document number: 200501462

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 2006506478

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 1200501683

Country of ref document: VN

WWE Wipo information: entry into national phase

Ref document number: 20048167362

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2004725121

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020057019591

Country of ref document: KR

ENP Entry into the national phase

Ref document number: PI0409429

Country of ref document: BR

WWW Wipo information: withdrawn in national office

Ref document number: 2004725121

Country of ref document: EP